Wednesday, 18 Sep 2019

You are here

Dietary Intake Triggers Inflammation

Although much has been made of the potential for the microbiome to shape immune responses and play a role in chronic inflammation, the manipulation of diet or microbiome to improve disease outcomes is still murky.

New research published in Nature Immunology builds on the potential importance of dietary intake showing it leads to an increase in macrophage derived IL-1 beta that, in turn, plays and important role in glucose regulation and subsequent inflammation.  (Citation source:

Dalmas et al have shown that intestinal macrophages increases during meal times and act as scavenger cells producing  IL-1beta in amounts that depend on blood glucose levels. IL-1beta, along with pancreatic production of insulin, helps regulate blood sugar levels. In addition, the bacteria consumed with nutrient intake may also amplify these regulatory mechanisms. 

These mechanisms regulating metabolism and immune system are dependent on both the bacteria and nutrients that are ingested during meals. With sufficient nutrients, the immune system is able to adequately combat foreign bacteria. Conversely, when there is a lack of nutrients, the few remaining calories must be conserved for important life functions at the expense of an immune response. This may go some way towards explaining why infectious disease may be more frequent with malnutrition or famine.

An analogy is seen with type 2 diabetes result in chronic inflammation, as increased glucose uptake into macrophages has pro-inflammatory effects downstream. In overweight individuals, this inflammatory response fails and may lead to diabetes.   Moreover, in diabetes, this IL-1 beta response and chronic inflammation may causes insulin-producing beta cells to die off.

Thus, dietary intake has strong effects on glucose metabolism and immunity mediated by IL-1β and insulin regulation.



The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Riociguat Fails in Systemic Sclerosis-Associated Digital Ulcers

Riociguat is an oral, selective soluble guanylate cyclase stimulator that has been studied in patients with digital ulcers (DU) due to systemic sclerosis (SSc) but study results show that short term (16 weeks) riociquat therapy does not sufficiently reduce the DU burden in SSc patients.

Nintedanib FDA Approved for Scleroderma Lung Disease

Last Friday, the US Food and Drug Administration approved Ofev (nintedanib) to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. ILD as a complication of SSc may lead to progressive loss of lung function and may be associated with a significant mortality risk. Prior to the approval of Olev, there were no FDA approved drugs for SSc-ILD.

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS).